Ocriplasmin Ophthalmic Side Effects
Medically reviewed by Drugs.com. Last updated on Jan 1, 2025.
Applies to ocriplasmin ophthalmic: parenteral injection.
Side effects include:
Vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, retinal edema.
For healthcare professionals
Applies to ocriplasmin ophthalmic: intravitreal solution.
General adverse events
The most commonly reported side effects included vitreous floaters, eye pain, photopsia, and blurred vision.[Ref]
Ocular
- Very common (10% or more): Vitreous floaters (up to 16.8%), macular hole (up to 15.8%), eye pain (up to 13.1%), photopsia (up to 11.8%), chromatopsia, conjunctival hemorrhage
- Common (1% to 10%): Abnormal optical coherence tomography (OCT), anterior chamber cell, anterior chamber flare, blurred vision, conjunctival edema, conjunctival hyperemia, cystoid macular edema, decreased best corrected visual acuity (BCVA), dry eye, dyschromatopsia, eye irritation, eye pruritus, eyelid edema, foreign body sensation in eyes, increased intraocular pressure, increased lacrimation, iritis, macular degeneration, macular edema, metamorphopsia, ocular discomfort, ocular hyperemia, photophobia, photopsia, reduced visual acuity, retinal breaks, retinal degeneration, retinal edema, retinal hemorrhage, retinal pigment epitheliopathy, subretinal fluid, visual impairment, vitreous detachment, vitreous hemorrhage, vitritis
- Uncommon (0.1% to 1%): Anterior chamber inflammation, conjunctival irritation, corneal abrasion, diplopia, eye inflammation, hyphema, lens subluxation, miosis, night blindness, retinal detachment, retinal tear, serious acute visual impairment, severe acute visual impairment, transient blindness, unequal pupils
- Frequency not reported: Dim vision, macular hole progression
- Postmarketing reports: Impaired pupillary reflex[Ref]
Nervous system
- Very common (10% or more): Abnormal color vision test, abnormal retinogram
- Common (1% to 10%): Abnormal macular reflex, increased intraocular pressure, visual field defect, visual symptoms perceived in the contralateral eye
- Frequency not reported: Scotoma[Ref]
Local
- Common (1% to 10%): Intravitreal injection procedure associated effects[Ref]
Immunologic
- Frequency not reported: Immunogenicity[Ref]
References
1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
2. Cerner Multum, Inc. "Australian Product Information."
3. (2012) "Product Information. Jetrea (ocriplasmin ophthalmic)." ThromboGenics Inc
More about ocriplasmin ophthalmic
- Compare alternatives
- Dosage information
- During pregnancy
- Drug class: miscellaneous ophthalmic agents
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Ocriplasmin ophthalmic side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.